We Work for Health | Washington

04/27/2026

The best healthcare decisions happen when the right people are in the room together.

We Work For Health is proud to sponsor the Washington Health Alliance’s Beyond the Bottom Line forum on May 13 in Seattle, a full-day gathering of employers, health plans, providers, and community leaders tackling affordability and quality head-on.

The day brings together nationally-recognized keynote speakers, reactor panels, and candid cross-sector conversations with people who are serious about getting healthcare right.

Join us.

Register here: https://wahealthalliance.org/health-forum-seattle/

04/24/2026

" would tie what Americans pay for certain medicines to prices set by foreign governments. Those governments don’t just negotiate prices differently; they often decide which treatments patients can access using rigid formulas."

https://www.pennlive.com/opinion/2026/04/drug-price-controls-sound-good-until-youre-the-cancer-patient-they-leave-behind-opinion.html

04/22/2026

Healthcare costs keep climbing. Quality gaps persist. Employers face mounting pressure to do more with less.

On May 13, We Work For Health is proud to sponsor Beyond the Bottom Line: Strategies for High-Value, Affordable Healthcare, a full-day convening in Seattle bringing together employers, providers, health plans, and community leaders.

The goal: practical, collaborative solutions. Not talking points.

If you work in benefits or healthcare purchasing, this conversation is for you.

Register here: https://wahealthalliance.org/health-forum-seattle/

The 2026 WHA Spring Forum brings together employers, health plans, care leaders, and policymakers to tackle the forces reshaping workforce health strategy.

04/20/2026

"America's life sciences leadership has delivered longer, healthier lives -- adding nearly a decade to U.S. life expectancy. Undermining that system risks not only our health but our global edge."

is bad for business: https://www.realclearhealth.com/articles/2026/04/15/drug_pricing_plan_risks_innovation_and_patients_1176879.html

04/17/2026

"Between 2024 and 2025, providers marked up discounted medicines by an average of 148%, generating an estimated $118.4 million in additional costs for New York State employee health plans and their enrollees."

Close policy loopholes: https://www.bxtimes.com/opinion-cindy-rubi-estrada-expanding-340b/

04/15/2026

"Tying U.S. [drug] prices to those set by other countries may create uncertainty for companies deciding where to invest in research and manufacturing."

is chipping away at U.S. leadership in research and development: https://www.fredericknewspost.com/opinion/columns/the-value-of-medical-innovation-and-stable-policy-environment/article_ded4d4bd-b02e-5d78-9cc9-21c6c55f79c5.html

04/14/2026

"If the program were functioning as intended, those higher revenues would translate into dramatically greater support for patients. But the numbers tell a different story."

https://www.dailyherald.com/20260406/columns/illinois-hospitals-are-cashing-in-on-a-program-meant-to-help-patients/

04/10/2026

"Notably, negotiations for these agreements are happening in private. There is no meaningful transparency around how prices are set, what drugs are subject to the deals, and what the manufacturers are expecting in return."

https://www.thirdway.org/report/what-most-favored-nation-means-for-prescription-drugs

04/08/2026

"Insurers, pharmacy benefit managers and third-party vendors have engineered a workaround that allows them to cash in at patients’ expense."

President Donald J. Trump has the opportunity to put over profit:

Last year, America’s pharmacy benefit managers and insurers pocketed a whopping $7 billion in co-pay assistance meant for patients.

04/06/2026

"Whether applied to prescription medicines or other essential goods, price controls may sound like a quick fix. In reality, they distort markets, discourage investment, reduce supply, and ultimately make affordability challenges worse."

https://www.starnewsonline.com/story/opinion/2026/03/21/price-controls-could-harm-north-carolinas-economy/89197201007/

04/03/2026

"Despite 340B providing discounted drugs to eligible hospitals to ensure access to care for vulnerable patient populations, 340B hospitals in most states are experiencing significantly more growth in assets than spending on uncompensated care, on a per bed basis."

04/01/2026

Tune in to understand how the U.S. could lose the biopharma leadership edge due to policy: https://www.youtube.com/watch?v=Hl93fvSdK_Q